Synlogic (SYBX) Reports Q3 Loss of $0.43, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 ends higher as CoreWeave results fuel AI optimism
- Oil prices edge up as investors weigh US-Iran talks deadlock against lower demand
- CoreWeave soars after fifth straight quarter of record revenue, raised guide
- Four key things investors will watch in Nvidia's earnings next week
- Silver could surge to $90 as investment demand takes over, Citi says
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Synlogic Reports Third Quarter 2018 Financial Results and Provides Program Updates
November 13, 2018 4:05 PM ESTAdvancement of SYNB1891, the first Synthetic Biotic immuno-oncology candidate to enable Investigational New Drug Application (IND) filing in 2H 2019
Ongoing clinical trials of SYNB1020 and SYNB1618 in patients with data expected in 2019
Management to host conference call and webcast at 5:00 pm ET today
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Synlogic, Inc. (Nasdaq: SYBX), a... More
